Venrock Adviser, LLC
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Venrock Adviser, LLC reported 35 stock positions worth $1.6 billion. Its top holding was Apogee Therapeutics (APGE) at 21.3% of the portfolio, followed by Enliven Therapeutics (ELVN, 6.0%) and 4D Molecular Therapeutics (FDMT, 5.9%). Compared with Q1 2024, it opened 6 new positions, sold out of 9, added to 6 and reduced 3. The biggest buy was a new position in Erasca (ERAS) and the biggest sale an exit from Hillevax (HLVX).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001615982
- Portfolio Value
- $1.6B (Q2 2024)
- SEC Filing
- 0001104659-24-089632 ↗ filed Aug 14, 2024
Holdings Value
Holdings 35 stocks · $1.6B
| APGE Apogee Therapeutics Inc. | 21.28% | 8,493,321 | $334.2M | No change |
| ELVN Enliven Therapeutics Inc. | 5.99% | 4,026,331 | $94.1M | No change |
| FDMT 4D Molecular Therapeutics Inc. | 5.88% | 4,400,000 | $92.4M | No change |
| OCUL Ocular Therapeutix Inc. | 5.56% | 12,762,462 | $87.3M | No change |
| DYN Dyne Therapeutics Inc. | 4.89% | 2,173,913 | $76.7M | No change |
| MRUS Merus NV | 4.76% | 1,263,214 | $74.7M | Reduce -29.4% |
| KALV Kalvista Pharmaceuticals Inc. | 4.69% | 6,249,731 | $73.6M | No change |
| PHVS Pharvaris NV | 4.07% | 3,395,606 | $63.8M | No change |
| SYRE Spyre Therapeutics Inc. | 4.02% | 2,685,448 | $63.1M | Add +23.6% |
| DNTH Dianthus Therapeutics Inc. | 3.45% | 2,094,373 | $54.2M | No change |
| VRDN Viridian Therapeutics Inc. | 3.22% | 3,882,671 | $50.5M | No change |
| COGT Cogent Biosciences Inc. | 3.05% | 5,684,167 | $47.9M | Add +10.8% |
| APLT Applied Therapeutics Inc. | 2.84% | 9,542,871 | $44.6M | Add +5.2% |
| ERAS Erasca Inc. | 2.44% | 16,216,216 | $38.3M | New |
| ATXS Astria Therapeutics Inc. | 2.09% | 3,608,645 | $32.8M | No change |
| EWTX Edgewise Therapeutics Inc. | 2.09% | 1,818,182 | $32.7M | No change |
| ORIC Oric Pharmaceuticals Inc. | 1.98% | 4,394,527 | $31.1M | No change |
| PRAX Praxis Precision Medicines I | 1.86% | 706,131 | $29.2M | Add +0.0% |
| ENGN Engene Holdings Inc. | 1.70% | 2,825,983 | $26.6M | Add +10.1% |
| CGEM Cullinan Therapeutics Inc. | 1.53% | 1,379,965 | $24.1M | New |
| TERN Terns Pharmaceuticals Inc. | 1.48% | 3,410,058 | $23.2M | No change |
| MERSANA THERAPEUTICS INC | 1.45% | 11,328,000 | $22.8M | No change |
| ZURA Zura Bio Ltd. | 1.34% | 6,023,166 | $21.1M | New |
| TSHA Taysha Gene Therapies Inc. | 1.28% | 9,000,000 | $20.2M | No change |
| ABVX Abivax SA-ADR | 1.13% | 1,345,780 | $17.8M | No change |
| ARVN Arvinas Inc. | 1.06% | 627,788 | $16.7M | No change |
| AQST Aquestive Therapeutics Inc. | 0.92% | 5,555,555 | $14.4M | No change |
| IPSC Century Therapeutics Inc. | 0.88% | 5,389,259 | $13.7M | Add +58.3% |
| CABA Cabaletta Bio Inc. | 0.74% | 1,563,952 | $11.7M | No change |
| TRVI Trevi Therapeutics Inc. | 0.65% | 3,422,637 | $10.2M | Reduce 0.0% |
| ADVM Adverum Biotechnologies Inc. | 0.64% | 1,467,048 | $10.1M | Reduce -5.7% |
| FRNM Freenome Inc. filed as PERCEPTIVE CAP SOLUTIONS COR | 0.48% | 750,000 | $7.5M | New |
| TNYA Tenaya Therapeutics Inc. | 0.31% | 1,555,556 | $4.8M | No change |
| ARCA BIOPHARMA INC | 0.21% | 866,375 | $3.3M | New |
| CASIF Casi Pharmaceuticals Inc. | 0.04% | 111,686 | $614K | New |
Portfolio Sells Q1 2024 → Q2 2024
| HLVX Hillevax Inc. | Sold out | 0.00% | −1.64 |
| CELC Celcuity Inc. | Sold out | 0.00% | −1.00 |
| IMTX Immatics NV | Sold out | 0.00% | −0.87 |
| LYRA Lyra Therapeutics Inc. | Sold out | 0.00% | −0.76 |
| CGON CG Oncology Inc. | Sold out | 0.00% | −0.73 |
| ADVM Adverum Biotechnologies Inc. | Reduce -5.7% | 0.64% | −0.41 |
| MLYS Mineralys Therapeutics Inc. | Sold out | 0.00% | −0.34 |
| SLRN Acelyrin Inc. | Sold out | 0.00% | −0.30 |
| EYPT Eyepoint Inc. | Sold out | 0.00% | −0.25 |
| OLMA Olema Pharmaceuticals Inc. | Sold out | 0.00% | −0.04 |
| TRVI Trevi Therapeutics Inc. | Reduce 0.0% | 0.65% | +0.09 |
| MRUS Merus NV | Reduce -29.4% | 4.76% | +0.93 |
Portfolio Buys Q1 2024 → Q2 2024
| ERAS Erasca Inc. | New | 2.44% | +2.44 |
| CGEM Cullinan Therapeutics Inc. | New | 1.53% | +1.53 |
| COGT Cogent Biosciences Inc. | Add +10.8% | 3.05% | +1.41 |
| ZURA Zura Bio Ltd. | New | 1.34% | +1.34 |
| FRNM Freenome Inc. | New | 0.48% | +0.48 |
| ARCA BIOPHARMA INC | New | 0.21% | +0.21 |
| IPSC Century Therapeutics Inc. | Add +58.3% | 0.88% | +0.20 |
| SYRE Spyre Therapeutics Inc. | Add +23.6% | 4.02% | +0.10 |
| CASIF Casi Pharmaceuticals Inc. | New | 0.04% | +0.04 |
| APLT Applied Therapeutics Inc. | Add +5.2% | 2.84% | −0.10 |
| PRAX Praxis Precision Medicines I | Add +0.0% | 1.86% | −0.19 |
| ENGN Engene Holdings Inc. | Add +10.1% | 1.70% | −0.37 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 33 | $3.3B | APGE, ORKA, ERAS, SYRE, DNTH |
| Q1 2026 | 33 | $2.7B | APGE, ERAS, ORKA, SYRE, KALV |
| Q4 2025 | 27 | $2.0B | APGE, ORKA, VRDN, SYRE, KALV |
| Q3 2025 | 33 | $1.8B | APGE, MTSR, OCUL, CDTX, VRDN |
| Q2 2025 | 31 | $1.3B | APGE, OCUL, MTSR, ELVN, KALV |
| Q1 2025 | 37 | $1.2B | APGE, MTSR, OCUL, ELVN, KALV |
| Q4 2024 | 37 | $1.5B | APGE, OCUL, ELVN, PRAX, VRDN |
| Q3 2024 | 38 | $1.9B | APGE, OCUL, ELVN, VRDN, APLT |
| Q2 2024 | 35 | $1.6B | APGE, ELVN, FDMT, OCUL, DYN |
| Q1 2024 | 38 | $2.1B | APGE, FDMT, OCUL, SYRE, MRUS |